KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Change in Taxes (2016 - 2017)

Historic Change in Taxes for Teva Pharmaceutical Industries (TEVA) over the last 6 years, with Q1 2017 value amounting to $54.0 million.

  • Teva Pharmaceutical Industries' Change in Taxes fell 7631.58% to $54.0 million in Q1 2017 from the same period last year, while for Mar 2017 it was $347.0 million, marking a year-over-year decrease of 5422.16%. This contributed to the annual value of $521.0 million for FY2016, which is 1782.33% down from last year.
  • Teva Pharmaceutical Industries' Change in Taxes amounted to $54.0 million in Q1 2017, which was down 7631.58% from $57.0 million recorded in Q4 2016.
  • Over the past 5 years, Teva Pharmaceutical Industries' Change in Taxes peaked at $249.0 million during Q4 2015, and registered a low of -$222.0 million during Q2 2013.
  • Its 5-year average for Change in Taxes is $103.4 million, with a median of $104.0 million in 2015.
  • In the last 5 years, Teva Pharmaceutical Industries' Change in Taxes skyrocketed by 123333.33% in 2014 and then plummeted by 7710.84% in 2016.
  • Teva Pharmaceutical Industries' Change in Taxes (Quarter) stood at $114.0 million in 2013, then skyrocketed by 63.16% to $186.0 million in 2014, then soared by 33.87% to $249.0 million in 2015, then plummeted by 77.11% to $57.0 million in 2016, then dropped by 5.26% to $54.0 million in 2017.
  • Its Change in Taxes stands at $54.0 million for Q1 2017, versus $57.0 million for Q4 2016 and $207.0 million for Q3 2016.